title: Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
authors.forename: Philippe
authors.initials: P
authors.lastname: Halfon
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.forename: Hacène
authors.initials: H
authors.lastname: Khiri
authors.forename: Guillaume
authors.initials: G
authors.lastname: Pénaranda
authors.forename: Agnes
authors.initials: A
authors.lastname: Martineau
authors.forename: Valérie
authors.initials: V
authors.lastname: Oulès
authors.forename: Jérôme
authors.initials: J
authors.lastname: Courcambeck
authors.forename: Patrick
authors.initials: P
authors.lastname: Philibert
mesh_terms: D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D016333:HIV Protease; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009154:Mutation; D017361:Viral Nonstructural Proteins / Q000235:genetics*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D016333:HIV Protease; D017320:HIV Protease Inhibitors; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C514803:p16 protease, Human immunodeficiency virus 1